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Abstract
 
Aims
 
This 24-month, multi-national, open-label, parallel group trial investigated the long-term efficacy and safety of
insulin detemir and Neutral Protamine Hagedorn insulin in combination with mealtime insulin aspart in patients with
Type 1 diabetes using a treat-to-target concept.
 
Methods
 
Patients were randomized 2 : 1 to detemir (
 
n
 
 = 331) or NPH (
 
n
 
 = 166) groups. Basal insulin was initiated once
daily (evening) and titrated individually based on self-measured plasma glucose (PG) levels, aiming for pre-breakfast and
pre-dinner targets 
 
≤
 
 6.0 mmol/l. A second basal morning dose could be added according to pre-defined criteria.
 
Results
 
After 24 months, superiority of glycated haemoglobin (HbA
 
1c
 
) was achieved with detemir compared to NPH
(detemir 7.36%, NPH 7.58%, mean difference 
 
−
 
0.22% points) [95% confidence interval (CI) 
 
−
 
0.41 to 
 
−
 
0.03%], with
reductions of 0.94% and 0.72% points, respectively. Fasting PG (FPG
 
lab
 
) was also lower with detemir (detemir 8.35 mmol/
l, NPH 9.43 mmol/l; 
 
P
 
 = 0.019). Twenty-two per cent of patients treated with detemir reached an HbA
 
1c
 
 
 
≤
 
 7.0% in the absence
of confirmed hypoglycaemia during the last month of treatment vs. 13% on NPH (
 
P
 
 = 0.019). Risk of major and nocturnal
hypoglycaemia was 69% and 46% lower with detemir than with NPH (
 
P 
 
< 0.001), respectively; patients treated with
detemir gained less weight (detemir 1.7 kg, NPH 2.7 kg; 
 
P
 
 = 0.024). The overall safety profile was similar in the two
groups and treatment with detemir did not result in any unexpected findings.
 
Conclusions
 
Long-term treatment with the insulin analogues detemir + aspart was superior to NPH + aspart in reducing
HbA
 
1c
 
, with added benefits of less major and nocturnal hypoglycaemia and less weight gain.
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Introduction
 
Studies such as the DCCT have shown that intensive insulin
therapy can improve glycaemic control and thereby reduce the
risk of micro- and macrovascular complications faced by
patients with Type 1 diabetes [1,2]. However, as glycated hae-
moglobin (HbA
 
1c
 
) is reduced, the risks of hypoglycaemia [3]
and weight gain increase [4] and become the main barriers for
obtaining good glycaemic control [5–7]. These adverse effects
may be more pronounced with conventional insulin products,
which are characterized by a high degree of variation in
absorption and pharmacodynamic profiles that are not well
matched with physiological insulin requirements [8–10].
During the last decade, both rapid-acting and basal insulin
analogues with more physiological and predictable action profiles
have been developed. These are generally at least as effective in
reducing HbA
 
1c
 
 as conventional human insulin, and are associated
with benefits including reductions in post-prandial plasma glucose,
lower risk of hypoglycaemia and less weight gain [7,11]. However,
to date, many of the trials reported with these analogues have
been of too limited duration to establish long-term efficacy and
safety or the applied glycaemic targets have been inadequate to
demonstrate the full potential of such analogue regimens.
Detemir is a long-acting basal soluble acylated analogue
of human insulin with a protracted action profile because of
hexamer stabilization at the injection site and buffering of
insulin concentrations via albumin binding in the blood [12].
Clinical trials of 
 
≤
 
 1 year duration have shown that detemir is
associated with comparable HbA
 
1c
 
, less variability in fasting
plasma glucose (FPG), less nocturnal hypoglycaemia and less
weight gain compared to intermediate-acting NPH [13–16].
The current trial is the first to investigate the long-term
(24 months) efficacy and safety of a basal–bolus regimen
with detemir or NPH in combination with aspart at meals in
patients with Type 1 diabetes using a treat-to-target concept.
 
Subjects and methods
 
Design
 
The trial was performed at 33 investigational sites in 10 coun-
tries worldwide. Patients were randomized to detemir or NPH
in a 2 : 1 ratio using a telephone randomization system. Because
detemir and NPH are visually distinguishable and patients were
to self-administer insulin throughout the trial, an open-labelled
design was used. The trial included 13 scheduled visits and an
extensive number of telephone contacts to ensure close contact
between participants and investigators.
 
Patients
 
Patients [
 
≥
 
 18 years, with an HbA
 
1c
 
 
 
≤
 
 11.0% and body mass
index (BMI) 
 
≤
 
 35.0 kg/m
 
2
 
] with a history of Type 1 diabetes 
 
≥
 
 1
year treated on a basal–bolus insulin regimen for 
 
≥
 
 3 months
and able and willing to self-measure plasma glucose were
enrolled. Individuals with proliferative retinopathy or maculopathy,
other significant medical disorders, recurrent major hypoglycaemia,
allergy to insulin and pregnant or breast-feeding women were
excluded. The trial was conducted in accordance with Good
Clinical Practice [17] and the Declaration of Helsinki [18] and
was approved by the local ethics committees. Prior to trial entry,
all participants gave written informed consent.
 
Titration and treatment
 
All patients started on a once-daily basal insulin regimen
and administered either detemir (Levemir®
 
, 
 
Novo Nordisk A/S,
Bagsvaerd, Denmark 100 U/ml) or NPH (Insulatard®, Novo
Nordisk A/S, 100 IU/ml) at any time during the evening. Aspart
(NovoRapid®, Novo Nordisk A/S, 100 U/ml) was injected
immediately before each main meal. Basal insulin was admin-
istered in the thigh and aspart in the abdomen. Patients trans-
ferred from a once-daily basal insulin regimen started treatment
with detemir or NPH at an identical number of units, while
those transferred from a twice-daily regimen initiated treatment
at 70% of the previous total daily basal insulin dose. Basal insulin
was titrated individually throughout the trial aiming for a PG
target 
 
≤
 
 6.0 mmol/l before breakfast and dinner. Participants
were instructed in the use and calibration of blood glucose meters
and were asked to measure PG pre-breakfast and pre-dinner on
three consecutive days prior to each contact. Based on the aver-
age of these measurements, the investigators titrated the basal
insulin dose according to a simple algorithm (Table 1). If the
FPG target was achieved while pre-dinner PG values remained
above target, the basal evening dose could be increased as long as
nocturnal hypoglycaemia did not occur. A second basal insulin
dose could be added in the morning if the pre-dinner PG target
was not achieved with use of the algorithm and after optimiza-
tion of bolus insulin. The basal morning dose was initiated at
4 U and titrated according to the same algorithm as used for the
evening dose (Table 1). Aspart was titrated according to local
practice to achieve a post-prandial PG level 
 
≤
 
 9.0 mmol/l. A
central surveillance committee reviewed the PG concentrations
and the prescribed basal insulin doses throughout the trial and
contacted the investigator in case of recurrent deviations from the
algorithm or in case of missing data.
During the first 12 weeks, patients were in weekly contact
with the investigator or research team (by phone, fax or e-mail).
Thereafter, contact was made at least every month.
Table 1 Algorithm used for titration of the basal insulin dose
FPG or pre-evening meal PG value 
(based on average SMPG values)
Adjustment of 
insulin dose (U)
> 15 mmol/l +6 U
10.1–15.0 mmol/l +4 U
6.1–10.0 mmol/l +2 U
≤ 6.0 mmol/l No adjustment
If one SMPG measurement:
3.1–4.0 mmol/l −2 U
< 3.1 mmol/l −4 U
FPG, fasting plasma glucose; SMPG, self-monitored plasma 
glucose; U, units.
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Antibody assessment
 
Blood samples for analysis of insulin antibodies were drawn
at randomization and after 64 and 105 weeks of treatment.
To avoid interference from detemir in the blood during insulin
antibody determination, patients treated with detemir were
switched to NPH 4–8 days prior to blood sampling for antibody
analyses at these visits. For safety reasons, the NPH dose was
reduced by 20% during this period and after blood sampling
the patient was transferred back to detemir at the same dose as
before the switch.
 
Analytical methods
 
Blood samples for analysis of HbA
 
1c
 
 and FPG
 
lab
 
 were drawn
approximately every 3 months. HbA
 
1c
 
 was determined by HPLC
(Bio-Rad Variant, Bio-Rad Laboratories GmbH, Munich,
Germany), (reference range of assay: 4.3–6.1%). FPG
 
lab
 
 was
analysed by a hexokinase method (Gluco-quant®; Roche
Diagnostics GmbH, Mannheim, Germany). Standard analyses
of haematology, biochemistry and lipids were performed by
Laboratorium für Klinische Forschung, Raisdorf, Germany. SMPG
was measured using a glucose meter (Medisense Precision
Xtra™ or Optimum Plus™; Abbott Diabetes Care, Delkenheim,
Germany). Use of test strips calibrated to PG values ensured
that capillary blood concentrations were displayed as PG values.
Body weight was measured at all scheduled visits. Hip/waist
ratio was calculated as the mean of three measurements and skin-
fold thickness was measured using callipers. All SMPG values
< 3.1 mmol/l as well as signs and symptoms of hypoglycaemia
were recorded in the patients’ diaries and included in the analysis
of hypoglycaemia. Insulin antibodies (detemir-specific, aspart-
specific and antibodies cross-reacting between detemir and aspart)
were analysed by MDS Pharma Services, Fehraltorf, Switzerland
using a subtraction RIA technique [19] modified for determination
of detemir antibodies. All blood samples were obtained in the
morning before administration of insulin. ECG and fundoscopy/
fundus photography, physical examination and vital signs were
evaluated at randomization and after 1 and 2 years of treatment.
 
Statistical analyses
 
The trial was designed as a non-inferiority trial using a 2 : 1
randomization. The primary end-point, HbA
 
1c
 
 after 24 months,
was tested for non-inferiority using a two-sided test at a 5%
significance level by applying a closed testing procedure [20].
A total of 489 patients were needed to obtain 245 evaluable
patients on detemir and 123 on NPH to detect a clinically
relevant difference of 0.4% in HbA
 
1c
 
 with a power of 85%,
assuming a standard deviation (
 
SD
 
) for HbA
 
1c
 
 of 1.2 and an ex-
pected drop-out rate of 25%. HbA
 
1c
 
 was analysed by an
ANCOVA model with treatment and country as fixed effects and
baseline HbA
 
1c
 
 value as a covariate. FPG
 
lab
 
, change in weight,
hip/waist ratio, skin-fold thickness and leptin concentrations
were analysed after 24 months using similar models with corre-
sponding baseline values as covariates. The percentage of
patients who reached HbA
 
1c
 
 
 
≤
 
 7.0% at the end of the trial
without symptomatic hypoglycaemia with a PG < 4.0 mmol/l
or any single PG value < 3.1 mmol/l during the last month of
treatment was analysed using Fisher’s exact test. Within-patient
variation (
 
SD
 
), based on the average of all available SMPG
pre-breakfast and pre-dinner measurements during the last week
of treatment, was analysed using a mixed model. Nine-point
SMPG profiles, recorded during the last week of treatment, were
analysed using a repeated measures model.
Hypoglycaemic episodes were classified as major if assistance
from another person was required, as minor if PG < 3.1 mmol/l
and the individual dealt with the episode him/herself, and as
symptoms only if episodes were not confirmed by a PG mea-
surement and no assistance was required. Relative risk of nocturnal
(23:00 to 06:00 h) hypoglycaemic episodes was tested separately.
Changes in insulin antibodies were based on analyses of blood
samples obtained at weeks 64 and 105. The statistical ANCOVA
model included country and time as fixed effects with total
basal insulin dose and HbA
 
1c
 
 at end of trial and baseline anti-
body levels as covariates.
 
Results
 
Patient disposition
 
Of the 497 patients randomized, 495 were exposed and
approximately 85% completed the trial (Fig.  1). A slightly
higher proportion of patients on detemir withdrew because of
adverse events, while withdrawal because of non-compliance
was more common in the NPH group. A fairly large proportion
of patients in both arms withdrew for ‘other’ unspecified
reasons. With the exception of one patient treated with detemir,
who withdrew because of concerns of hypoglycaemia, these
were all non-related to trial products.
Patient characteristics were similar between the two groups
(Table 2). This was also the case with respect to diabetic
complications and concomitant illnesses (not shown). Appro-
ximately 60% of patients in both groups were on a once-daily
basal insulin regimen prior to the trial and around 90% of all
patients were treated with NPH at baseline. Mean daily insulin
doses were similar between the two groups (Table 2).
 
Glycaemic control
 
HbA
 
1c
 
 decreased by 0.94% with detemir and by 0.72% with NPH
during the trial; glycaemic control was superior with detemir after
24 months, with a mean difference (detemir—NPH) of 
 
−
 
0.22%
points (Table 3). The difference in HbA
 
1c
 
 between the two treat-
ment groups was most pronounced during the last 6 months
of the trial (Fig. 2). FPG
 
lab
 
 also decreased to a larger extent with
detemir than with NPH, with reductions of 3.01  mmol/l vs.
1.93 mmol/l  (
 
P
 
 = 0.019) (Table 3). Within-patient variation in
self-measured FPG was lower with detemir than with NPH (
 
SD
 
2.18 mmol/l vs. 2.52 mmol/l; 
 
P
 
 < 0.001), while no statistically
significant difference was found in pre-evening meal PG vari-
ation (
 
SD
 
 2.50 mmol/l vs. 2.46 mmol/l; 
 
P
 
 = NS). Self-measured
nine-point PG concentrations were generally reduced in both
groups at all times of the day, but the shape of these profiles
could not be considered parallel after 24 months of treatment
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(
 
P
 
 = 0.004). The main differences between treatments were
related to higher mean PG levels pre-evening meal and lower mean
concentrations before breakfast with detemir compared to NPH.
After 24 months, 38% of patients had achieved an HbA
 
1c
 
≤
 
 7.0% with detemir compared to 29% with NPH (
 
P
 
 = 0.043),
while 22% of patients on detemir and 13% on NPH reached
this level of control in the absence of confirmed hypoglycaemia
during the last month of treatment (
 
P
 
 = 0.019). Based on SMPG
recordings, 52% of patients on detemir and 41% on NPH met
the PG target of 
 
≤
 
 6.0 mmol/l pre-breakfast, while 40% and
32%, respectively, met this target pre-evening meal.
 
Hypoglycaemia
 
Detemir was associated with a 69% lower risk of major
hypoglycaemic episodes compared to NPH (
 
P
 
 < 0.001), while
the overall risk of hypoglycaemia was comparable between
treatments (Table 4). The highest frequency of hypoglycaemic
episodes was observed during the first 3 months of the trial in
both treatment groups. The risk of nocturnal hypoglycaemia
was 46% lower with detemir than with NPH (
 
P
 
 < 0.001). The
reduced risk of nocturnal episodes was observed regardless of
classification and was reflected by a lower number of nocturnal
hypoglycaemic episodes per patient per year with detemir
relative to NPH (3.4 vs. 6.4 episodes). Nocturnal hypoglycaemia
constituted about 13% of all episodes recorded during treatment
with detemir compared to 18% with NPH.
Hypoglycaemic episodes were reported as serious adverse
events for 14 (4.3%) patients on detemir (18 episodes, of which
FIGURE 1 Patient disposition.
FIGURE 2 Change in mean glycated haemoglobin (HbA1c) over time. 
Detemir, black circles; Neutral Protamine Hagedorn, white circles.
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six were comas) compared to 12 (7.3%) patients on NPH
(35 episodes, of which eight were comas).
 
Weight and body composition
 
The increase in body weight was less with detemir than with
NPH (1.7 kg vs. 2.7 kg; 
 
P
 
 = 0.024). Adjustment for HbA
 
1c
 
 at
end of trial gave similar results. Slight and similar changes in
hip/waist ratio, skin-fold thickness and leptin levels were
observed in both groups, but there were no statistically significant
differences between groups after 24 months (Table 3).
 
Insulin regimen and doses
 
After 24 months of treatment, the median (
 
SD
 
) daily dose of
detemir was 0.56 (0.40) U/kg compared to 0.46 (0.27) IU/kg
with NPH and the median doses of aspart were 0.43 (0.29) and
0.38 (0.22) U/kg, respectively. A total of 37% of patients com-
pleted the trial on a once-daily detemir regimen compared to
45% on NPH (NS). The median time to transfer from a once-daily
to a twice-daily regimen was approximately 9 months with both
treatments (NS). In general, the median dose ratio (evening/
morning) was 1.2 with detemir compared to 1.5 with NPH.
Table 2 Baseline characteristics
Patients exposed to treatment, n (%)
Detemir 
331 (100.0%)
NPH 
164 (100.0%)
All 
495 (100.0%)
Sex
Female 147 (44.4) 77 (47.0) 224 (45.3)
Male 184 (55.6) 87 (53.0) 271 (54.7)
Ethnic origin
White 244 (73.7) 129 (78.7) 373 (75.4)
Black 3 (0.9) 1 (0.6) 4 (0.8)
Asian/Pacific Islander 66 (19.9) 32 (19.5) 98 (19.8)
Other 18 (5.4) 2 (1.2) 20 (4.0)
Diabetes duration (years) 12.7 (1.0–50.4) 13.5 (1.1–49.4) 13.0 (1.0–50.4)
Age (years) 35 (18–75) 35 (18–70) 35 (18–75)
BMI (kg/m2) 24.7 (15.4–34.6) 24.7 (16.9–34.7) 24.7 (15.4–34.7)
Weight (kg)* 71.2 (39.5–128.4) 70.9 (33.6–119.0) 71.1 (33.6–128.4)
HbA1c (%)* 8.3 (5.0–11.6) 8.4 (5.3–11.4) 8.3 (5.0–11.6)
FPG (mmol/l)* 11.4 (0.7–33.9) 11.7 (2.8–30.4) 11.5 (0.7–33.9)
Pre-trial insulin regimen
1 basal + 3 bolus 194 (58.6) 100 (61.0) 294 (59.4)
2 basal + 3 bolus 88 (26.6) 42 (25.6) 130 (26.3)
Pre-trial daily insulin dose
Basal insulin (IU/kg) 0.37 (0.04–1.10) 0.36 (0.06–1.24) 0.37 (0.04–1.24)
Meal-time insulin (U/kg) 0.46 (0.02–1.67) 0.45 (0.03–1.29) 0.46 (0.02–1.67)
Values are n (%) or mean (range).
NPH, Neutral Protamine Hagedorn; BMI, body mass index; HbA1c, glycated haemoglobin; FPG, fasting plasma glucose.
*HbA1c, FPG and weight recorded at or before randomization.
Table 3 Efficacy results after 24 months; ITT
Detemir NPH Detemir—NPH
P-value n Mean (SE) n Mean (SE) Mean (95% CI)
HbA1c (%) 320 7.36 (0.06) 159 7.58 (0.08) −0.22 (−0.41 to −0.03) 0.022*
FPGlab (mmol/l) 318 8.35 (0.27) 158 9.43 (0.38) −1.08 (−1.98 to −0.18) 0.019
Weight (kg) 320 72.92 (0.26) 159 73.91 (0.37) −0.99 (−1.86 to −0.13) 0.024
Hip/waist ratio (cm/cm) 313 1.17 (0.01) 157 1.18 (0.01) −0.01 (−0.03 to 0.01) 0.277
Abdominal skin-fold thickness (mm) 312 23.48 (0.47) 157 22.54 (0.65) 0.94 (−0.60 to 2.48) 0.231
Leptin (μg/l) 311 11.07 (0.40) 158 11.53 (0.55) −0.46 (−1.77 to 0.85) 0.493
All end-points were compared between the treatment groups by fitting an analysis of covariance (ANCOVA) with treatment and country as 
fixed effects and baseline value as a covariate. For hip and waist measurements, an average of the three repeated measurements was taken before 
calculating the ratio. Mean and standard error (SE) are estimated from the model.
NPH, Neutral Protamine Hagedorn; CI, confidence interval; HbA1c, glycated haemoglobin; FPG, fasting plasma glucose.
*The superiority criterion was fulfilled for detemir relative to NPH.
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Adverse events
 
Adverse events were reported in about 80% of patients in both
groups. These were judged by the investigator as being possibly
or probably related to trial drug in 10.9% and 17.1% of all
patients exposed to detemir and NPH, respectively. Serious
adverse events were reported for about 15–17% of treated
patients and were considered possibly or probably related to
trial drug in a total of 4.2% and 6.7% of patients treated with
detemir and NPH, respectively. The latter difference between
treatments could mainly be attributed to a higher frequency of
hypoglycaemia and hypoglycaemic coma with NPH.
Four deaths were reported in the detemir group: cardio-
respiratory arrest in relation to status epilepticus, sudden death,
bronchopneumonia and myocardial infarction following
surgery. No deaths were reported in the NPH groups. All of
these events were judged as being unlikely related to trial drug
by the investigator. Withdrawal because of adverse events
was more common with detemir and included eight events
considered as possibly or probably related to trial drug. Three
of these were non-serious injection site disorders of mild or
moderate severity, while the others included hypoglycaemic
coma plus humeral fracture, retinal detachment, weight gain
and allergic dermatitis.
 
Insulin antibodies and other safety data
 
Antibody formation increased between baseline and 64 weeks
of treatment with detemir, but stabilized and tended to decrease
during the second year (not shown). Statistical analyses of
changes in antibody levels between week 64 and week 105
showed small, but statistically significant, reductions in
detemir-specific antibodies (
 
P
 
 = 0.001), cross-reacting antibodies
and aspart-specific antibodies (
 
P
 
 < 0.05 for both).
No apparent differences were observed between treatments
in standard laboratory parameters, vital signs, ECG or fundos-
copy/fundus photography during the trial.
 
Discussion
 
This is the first trial to apply a treat-to-target concept with
detemir in patients with Type 1 diabetes. This approach was
used to achieve and maintain the best possible glycaemic
control throughout the trial. After 24 months, mean HbA
 
1c
 
was around 7.4% and 7.6% with detemir and NPH, respectively,
reflecting fairly good control even if recommended levels of
HbA
 
1c
 
 < 7.0% [21] were not achieved. This reflects the fact
that optimal glycaemic control is very difficult to attain in a
proportion of patients, even with relatively frequent and close
contact with the clinical sites, and emphasizes the need for
continued focus on insulin dose titration.
Six months into the trial, blinded review of the pre-breakfast
and pre-evening meal PG concentrations revealed that PG
targets were not achieved in a substantial proportion of patients
and a protocol amendment was implemented to ensure more
frequent contact between patients and investigators during
the last year of the trial. As shown in Fig. 2, the difference in
HbA
 
1c
 
 between treatments was most pronounced during the
last 6 months. This may reflect that full optimization of
detemir was only achieved as investigators gained experience
and confidence with use of the drug and participants became
less afraid of hypoglycaemia. Considering the lag time between
effective insulin titration and resulting improvement in HbA
 
1c
 
,
the most plausible explanation for the lower HbA
 
1c
 
 observed
with detemir at the end of trial is that it can be titrated more
aggressively than NPH without unacceptable risk of hypogly-
caemia. Thus, even at a slightly lower mean HbA
 
1c
 
, patients
treated with detemir had a markedly reduced risk of both
Table 4 Summary of treatment-emergent hypoglycaemic episodes
Detemir NPH Relative risk (Detemir/NPH)
Patients 
n (%)
Number of 
episodes
Episodes/
patient/year
Patients 
n (%)
Number of 
episodes
Episodes/
patient/year
Estimate 
(95% CI) P-value
All 309 (93.4) 15 867 26.2 159 (97.0) 11 052 36.0 0.74 (0.51–1.07)  0.112
Major 49 (14.8)  148 0.2 42 (25.6)  237 0.8 0.31 (0.16–0.58) < 0.001
Minor 301 (90.9) 13 152 21.7 158 (96.3)  8659 28.2 0.78 (0.52–1.16)  0.220
Symptoms only 221 (66.8)  2334 3.9 122 (74.4)  2026 6.6 0.58 (0.39–0.86)  0.007
Nocturnal 237 (71.6)  2026 3.4 124 (75.6)  1954 6.4 0.54 (0.40–0.71) < 0.001
Major 18 (5.4)  34 0.1 25 (15.2)  66 0.2 0.27 (0.13–0.57)  0.001
Minor 222 (67.1)  1667 2.8 120 (73.2)  1508 4.9 0.57 (0.42–0.77) < 0.001
Symptoms only 107 (32.3)  301 0.5 60 (36.6)  358 1.2 0.44 (0.29–0.67) < 0.001
Three hundred and sixty-three hypoglycaemic episodes could not be classified as major, minor or symptoms only and are only included in the 
total number of episodes. Several episodes had missing time and were therefore not considered as nocturnal. Forty-six nocturnal hypoglycaemic 
episodes could not be classified as major, minor or symptoms only. Hypoglycaemic episodes occurring during NPH treatment of patient 
randomized to detemir are excluded.
NPH, Neutral Protamine Hagedorn; n, number of patients having at least one hypoglycaemic episode; %, proportion of patients exposed in the 
treatment period having an episode; CI, confidence interval.
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major and nocturnal hypoglycaemic episodes while using a
higher median basal insulin dose. This is an important finding
because hypoglycaemia remains the main barrier for achieving
optimal glycaemic control [5,6].
In the DCCT, the event rate for severe hypoglycaemia
requiring assistance was 0.61 events per patient per year [22]
at a mean HbA1c of 7.2% [23]. In the current trial we find an
event rate with detemir of 0.2 episodes per patient per year
with detemir and 0.8 with NPH. The DCCT also found the
risk of severe hypoglycaemia was greatest during sleep [3].
This is not supported by our study: only 23% (34 of 148) of all
major episodes with detemir and 28% (66 of 237) with NPH
were nocturnal.
The lower risk of nocturnal hypoglycaemic episodes with
detemir is consistent with results from other clinical trials in
both Type 1 and Type 2 diabetes [13,15,16,24] and was
observed in spite of lower FPG concentrations. This could be
related to the reduced within-patient variation in FPG shown
for detemir relative to NPH, which is also in line with findings
from previous trials [13,14,16,25].
The combination of less within-patient variation in PG [25],
longer duration of action and a reduced peak effect observed
with detemir relative to NPH [26] probably signify that FPG
targets are achieved more easily without additional risk of
hypoglycaemia.
Weight gain is a side-effect of insulin therapy, which seems
to be inversely correlated to reduction in HbA1c [22,27].
Although a gain in weight was also observed with detemir
during the trial, the increase was markedly lower than that
with NPH in spite of a larger reduction in HbA1c. There were
no differences in changes in snacking during the trial between
the two treatment groups.
Weight gain adversely affects insulin sensitivity, lipid levels
and blood pressure and thereby increases the risk of cardiovascular
disease [4,7]. Weight gain may have a negative effect on patients’
self-perception and act as a barrier for optimizing insulin [28].
The DCCT showed that patients treated on an intensive insulin
regimen had a greater increase in BMI than expected during
the 6–9 years of treatment without any tendency to lose
accumulated weight [29]. Therefore, limiting the increase in
body weight associated with long-term insulin therapy is of
major importance.
Treatment with insulin detemir did not give rise to any
unexpected safety findings and the adverse event profile did
not give reasons for concern. The four deaths reported with
detemir were separate events that the investigator considered
as having an unlikely relation to trial drug; none of the events
were associated with reports of hypoglycaemia.
As expected, administration of detemir gave rise to the
formation of insulin antibodies in patients not previously
exposed to this insulin preparation. However, antibody levels
stabilized and tended to decrease during the second year of
treatment even though median doses of detemir increased.
Moreover, insulin antibodies did not appear to have any
impact on metabolic control.
In conclusion, long-term treatment with detemir using a
treat-to-target concept resulted in lower HbA1c levels than
NPH with reduced risk of major and nocturnal hypoglycaemia
and less weight gain. The general safety profile over 24 months
of treatment did not give rise to any concerns or unexpected
findings.
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